Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mindfulness | 2 | 2022 | 70 | 1.190 |
Why?
|
| Stress, Psychological | 5 | 2016 | 469 | 1.140 |
Why?
|
| Brain Mapping | 5 | 2016 | 232 | 1.020 |
Why?
|
| Brain | 8 | 2016 | 1553 | 0.900 |
Why?
|
| Brain Injuries | 3 | 2016 | 139 | 0.840 |
Why?
|
| Neural Pathways | 4 | 2016 | 98 | 0.670 |
Why?
|
| Encephalitis | 1 | 2019 | 34 | 0.620 |
Why?
|
| Memory Disorders | 1 | 2019 | 50 | 0.620 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2019 | 87 | 0.570 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2016 | 2162 | 0.550 |
Why?
|
| Hypertension | 1 | 2022 | 584 | 0.520 |
Why?
|
| Behavior, Animal | 2 | 2013 | 230 | 0.520 |
Why?
|
| Visual Cortex | 1 | 2016 | 26 | 0.520 |
Why?
|
| Alcoholism | 1 | 2019 | 318 | 0.500 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2016 | 159 | 0.500 |
Why?
|
| Corpus Striatum | 1 | 2016 | 97 | 0.490 |
Why?
|
| Recovery of Function | 2 | 2016 | 286 | 0.480 |
Why?
|
| Behavior Therapy | 1 | 2016 | 165 | 0.470 |
Why?
|
| Prefrontal Cortex | 4 | 2019 | 122 | 0.470 |
Why?
|
| Frontal Lobe | 3 | 2014 | 64 | 0.460 |
Why?
|
| Testosterone | 2 | 2005 | 121 | 0.450 |
Why?
|
| Corpus Callosum | 2 | 2016 | 42 | 0.440 |
Why?
|
| Tobacco Use Disorder | 2 | 2014 | 246 | 0.430 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2013 | 41 | 0.420 |
Why?
|
| Rats | 7 | 2016 | 1977 | 0.410 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 2179 | 0.390 |
Why?
|
| Cognition Disorders | 1 | 2013 | 217 | 0.380 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2016 | 619 | 0.330 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2005 | 88 | 0.310 |
Why?
|
| Hydrocortisone | 2 | 2001 | 193 | 0.300 |
Why?
|
| Obesity | 1 | 2016 | 1230 | 0.300 |
Why?
|
| Male | 20 | 2016 | 29717 | 0.290 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2022 | 74 | 0.290 |
Why?
|
| Adaptation, Psychological | 2 | 2005 | 265 | 0.260 |
Why?
|
| Rest | 3 | 2016 | 46 | 0.260 |
Why?
|
| Rats, Wistar | 3 | 2013 | 185 | 0.250 |
Why?
|
| Animals | 11 | 2019 | 20613 | 0.250 |
Why?
|
| Hippocampus | 2 | 2019 | 270 | 0.250 |
Why?
|
| Hostility | 1 | 2005 | 18 | 0.240 |
Why?
|
| Acclimatization | 1 | 2005 | 11 | 0.240 |
Why?
|
| Personality | 1 | 2005 | 29 | 0.240 |
Why?
|
| Brain Concussion | 2 | 2015 | 36 | 0.230 |
Why?
|
| Fear | 1 | 2004 | 70 | 0.220 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2003 | 8 | 0.220 |
Why?
|
| Serotonin | 1 | 2003 | 60 | 0.210 |
Why?
|
| Blood Pressure | 2 | 2022 | 509 | 0.210 |
Why?
|
| Nerve Net | 2 | 2015 | 97 | 0.200 |
Why?
|
| Adult | 9 | 2022 | 16736 | 0.190 |
Why?
|
| Appetitive Behavior | 1 | 2002 | 2 | 0.190 |
Why?
|
| Energy Metabolism | 2 | 2015 | 379 | 0.190 |
Why?
|
| Anti-Anxiety Agents | 1 | 2002 | 32 | 0.190 |
Why?
|
| Female | 13 | 2019 | 32709 | 0.180 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2002 | 97 | 0.180 |
Why?
|
| Child Abuse, Sexual | 1 | 2001 | 25 | 0.180 |
Why?
|
| Models, Animal | 1 | 2002 | 236 | 0.170 |
Why?
|
| Rats, Inbred SHR | 2 | 2016 | 5 | 0.160 |
Why?
|
| Alanine Transaminase | 1 | 2019 | 39 | 0.160 |
Why?
|
| Saliva | 1 | 2000 | 103 | 0.160 |
Why?
|
| Seasons | 1 | 2000 | 134 | 0.160 |
Why?
|
| Anxiety | 1 | 2002 | 423 | 0.150 |
Why?
|
| Athletic Injuries | 2 | 2015 | 83 | 0.140 |
Why?
|
| Motor Activity | 2 | 2014 | 346 | 0.140 |
Why?
|
| Rats, Inbred WKY | 1 | 2016 | 11 | 0.130 |
Why?
|
| Somatosensory Cortex | 1 | 2016 | 20 | 0.130 |
Why?
|
| Maze Learning | 2 | 2014 | 55 | 0.130 |
Why?
|
| Nucleus Accumbens | 1 | 2016 | 43 | 0.130 |
Why?
|
| Ethanol | 1 | 2019 | 322 | 0.130 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2001 | 397 | 0.130 |
Why?
|
| Gene Expression | 1 | 2019 | 837 | 0.120 |
Why?
|
| Weight Reduction Programs | 1 | 2016 | 57 | 0.120 |
Why?
|
| Armadillo Domain Proteins | 1 | 2016 | 23 | 0.120 |
Why?
|
| Axons | 1 | 2016 | 123 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 310 | 0.120 |
Why?
|
| Neuropsychological Tests | 2 | 2015 | 391 | 0.120 |
Why?
|
| Phosphates | 1 | 2015 | 92 | 0.120 |
Why?
|
| Depression | 1 | 2022 | 890 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 332 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 294 | 0.110 |
Why?
|
| Adolescent | 6 | 2015 | 6229 | 0.110 |
Why?
|
| Cytoskeletal Proteins | 1 | 2016 | 200 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 3387 | 0.110 |
Why?
|
| Humans | 12 | 2022 | 63149 | 0.110 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2014 | 12 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2016 | 488 | 0.110 |
Why?
|
| Parietal Lobe | 1 | 2014 | 28 | 0.110 |
Why?
|
| Fish Oils | 1 | 2014 | 43 | 0.110 |
Why?
|
| Gyrus Cinguli | 1 | 2014 | 57 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2013 | 147 | 0.100 |
Why?
|
| Anisotropy | 1 | 2013 | 60 | 0.100 |
Why?
|
| Functional Neuroimaging | 1 | 2013 | 14 | 0.100 |
Why?
|
| Methylphenidate | 1 | 2013 | 19 | 0.100 |
Why?
|
| Dietary Fats | 1 | 2014 | 175 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 733 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 658 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 1 | 2013 | 65 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2015 | 265 | 0.100 |
Why?
|
| Anger | 1 | 2012 | 23 | 0.100 |
Why?
|
| Reference Values | 2 | 2005 | 335 | 0.100 |
Why?
|
| Amygdala | 1 | 2012 | 83 | 0.090 |
Why?
|
| Psychometrics | 1 | 2013 | 375 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2016 | 3270 | 0.080 |
Why?
|
| Middle Aged | 4 | 2016 | 17480 | 0.080 |
Why?
|
| Mice | 2 | 2019 | 10816 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1543 | 0.070 |
Why?
|
| Young Adult | 5 | 2015 | 4673 | 0.070 |
Why?
|
| Time Factors | 1 | 2013 | 3754 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5625 | 0.060 |
Why?
|
| Corticosterone | 1 | 2005 | 23 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 2673 | 0.060 |
Why?
|
| Foxes | 1 | 2004 | 3 | 0.060 |
Why?
|
| Orchiectomy | 1 | 2004 | 33 | 0.060 |
Why?
|
| Odorants | 1 | 2004 | 17 | 0.060 |
Why?
|
| Pain Threshold | 1 | 2004 | 25 | 0.060 |
Why?
|
| Aggression | 1 | 2005 | 64 | 0.060 |
Why?
|
| Sexual Behavior, Animal | 1 | 2004 | 87 | 0.060 |
Why?
|
| Reaction Time | 1 | 2004 | 124 | 0.060 |
Why?
|
| Cerebrovascular Circulation | 1 | 2005 | 180 | 0.050 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2003 | 13 | 0.050 |
Why?
|
| United States | 1 | 2016 | 7824 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2004 | 345 | 0.050 |
Why?
|
| Motivation | 1 | 2004 | 285 | 0.050 |
Why?
|
| Buspirone | 1 | 2002 | 3 | 0.050 |
Why?
|
| Desipramine | 1 | 2002 | 3 | 0.050 |
Why?
|
| Chlordiazepoxide | 1 | 2002 | 4 | 0.050 |
Why?
|
| Yohimbine | 1 | 2002 | 9 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 47 | 0.050 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2002 | 20 | 0.050 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2002 | 19 | 0.050 |
Why?
|
| Clozapine | 1 | 2002 | 32 | 0.050 |
Why?
|
| Mesocricetus | 1 | 2002 | 94 | 0.050 |
Why?
|
| Fluoxetine | 1 | 2002 | 44 | 0.050 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2002 | 30 | 0.050 |
Why?
|
| Fasting | 1 | 2002 | 51 | 0.050 |
Why?
|
| Cricetinae | 1 | 2002 | 366 | 0.040 |
Why?
|
| Arousal | 1 | 2000 | 42 | 0.040 |
Why?
|
| Pituitary-Adrenal System | 1 | 2000 | 60 | 0.040 |
Why?
|
| Cholesterol | 1 | 2000 | 260 | 0.040 |
Why?
|
| Child | 2 | 2013 | 4520 | 0.030 |
Why?
|
| Wallerian Degeneration | 1 | 2016 | 8 | 0.030 |
Why?
|
| Phosphorus Isotopes | 1 | 2015 | 7 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2000 | 382 | 0.030 |
Why?
|
| Nucleosides | 1 | 2015 | 11 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2001 | 1988 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2015 | 78 | 0.030 |
Why?
|
| Universities | 1 | 2015 | 158 | 0.030 |
Why?
|
| Creatine | 1 | 2014 | 24 | 0.030 |
Why?
|
| Aspartic Acid | 1 | 2014 | 28 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 2016 | 297 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2014 | 100 | 0.030 |
Why?
|
| Athletes | 1 | 2015 | 109 | 0.030 |
Why?
|
| Locomotion | 1 | 2014 | 116 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2014 | 162 | 0.030 |
Why?
|
| Basal Ganglia | 1 | 2013 | 34 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2014 | 137 | 0.030 |
Why?
|
| Cerebellum | 1 | 2013 | 94 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1254 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 2107 | 0.020 |
Why?
|
| Aged | 1 | 2000 | 14333 | 0.010 |
Why?
|